Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients wit

Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients with B-cell ALL. Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating them with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.

Trechos de apoio da pauta: Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating them with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

• Ponto de atenção: novel.
• Ponto de atenção: antibody.
• Ponto de atenção: drug.

Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.